With respect to glaucoma risk factors, EFV treatment decreased, as compared to the control Apoj−/− group, the IOP from 17 to 14 mm Hg and CDR from 0.60 to 0.51, and increased the amplitudes of P1 (from 4.6 to 7.7 μM) and N2 (from 9.5 to 14.0 μM) in the PERG waveforms (Fig. 11C,D,E). The gene discussed is CLU; the disease is glaucoma.